A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) — Stella
A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)
Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(3 sites)
Thailand
Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok